Intramolecular Ring-Opening Decomposition of Aryl Azetidines.


Journal

ACS medicinal chemistry letters
ISSN: 1948-5875
Titre abrégé: ACS Med Chem Lett
Pays: United States
ID NLM: 101521073

Informations de publication

Date de publication:
14 Oct 2021
Historique:
received: 25 07 2021
accepted: 28 09 2021
entrez: 22 10 2021
pubmed: 23 10 2021
medline: 23 10 2021
Statut: epublish

Résumé

The ring strain present in azetidines can lead to undesired stability issues. Herein, we described a series of N-substituted azetidines which undergo an acid-mediated intramolecular ring-opening decomposition via nucleophilic attack of a pendant amide group. Studies were conducted to understand the decomposition mechanism enabling the design of stable analogues.

Identifiants

pubmed: 34676040
doi: 10.1021/acsmedchemlett.1c00402
pmc: PMC8521649
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1585-1588

Informations de copyright

© 2021 American Chemical Society.

Déclaration de conflit d'intérêts

The authors declare the following competing financial interest(s): All authors were employees and stockholders of Pfizer during the time this work was completed.

Références

Drug Metab Dispos. 2019 Nov;47(11):1247-1256
pubmed: 31492694
J Med Chem. 2020 Jun 25;63(12):6303-6314
pubmed: 32267691
Xenobiotica. 2016 Dec;46(12):1112-1121
pubmed: 26947511
Bioorg Med Chem Lett. 2011 Jan 1;21(1):34-7
pubmed: 21146986
J Med Chem. 2017 Jul 13;60(13):5673-5698
pubmed: 28574706
J Med Chem. 2012 Nov 26;55(22):9998-10009
pubmed: 23092294
J Med Chem. 2019 Aug 22;62(16):7383-7399
pubmed: 31310524

Auteurs

Guoyun Bai (G)

Discovery Sciences, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.

Thomas N O'Connell (TN)

Discovery Sciences, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.

Michael A Brodney (MA)

Medicine Design, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States.

Christopher R Butler (CR)

Medicine Design, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States.

Lara C Czabaniuk (LC)

Discovery Sciences, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.

Adam M Gilbert (AM)

Discovery Sciences, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.

Erik A LaChapelle (EA)

Medicine Design, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.

Chao Li (C)

Discovery Sciences, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.

Laura A McAllister (LA)

Medicine Design, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States.

Kevin Ogilvie (K)

Medicine Design, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.

Laurence Philippe (L)

Discovery Sciences, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.

Romelia Salomon-Ferrer (R)

La Jolla Laboratories, Pfizer Worldwide Research and Development, La Jolla, California 92121, United States.

Michael J Shapiro (MJ)

Discovery Sciences, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.

Jeremy T Starr (JT)

Discovery Sciences, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.

Daniel P Uccello (DP)

Discovery Sciences, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.

Jane M Withka (JM)

Discovery Sciences, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.

Jiangli Yan (J)

Discovery Sciences, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.

Matthew F Brown (MF)

Discovery Sciences, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.

Classifications MeSH